Hypothesis: Periodic mTOR rebound from weekly rapamycin dosing selectively upregulates the NAD+ salvage pathway in tissue-resident stem cells, producing rapid, measurable changes in DunedinPACE but not first-generation epigenetic clocks—offering a mechanistic link between mTOR cycling, NAD+ metabolism, and aging biomarker sensitivity.

Background: Unresolved Tensions in Longevity Interventions

The field lacks integrated models for how rapamycin dosing, NAD+ biology, and epigenetic clocks interact. Rapamycin's intermittent protocols aim to balance autophagy induction with immunosuppression risks, but mTOR rebound between doses remains a theoretical concern Rapamycin controversies. Meanwhile, NAD+ precursors like NMN are plagued by bioavailability questions, with intracellular concentrations around 3 μM in preclinical models, yet human tissue delivery is unproven [NAD+ precursors]. Biological age clocks add complexity: DunedinPACE tracks functional decline via 18 biomarkers, while Horvath clock reflects cumulative pan-tissue methylation Clock mechanisms. This triad suggests a feedback loop: rapamycin-induced mTOR dynamics might modulate NAD+ availability, which in turn influences epigenetic aging markers.

Mechanistic Insight: mTOR Rebound as a Catalyst for NAD+ Salvage

mTORC1 inhibition by rapamycin suppresses Nampt, the rate-limiting enzyme in the NAD+ salvage pathway. However, intermittent dosing could trigger compensatory mTOR rebound hyperactivation during off-periods, paradoxically upregulating Nampt expression in stem cell niches (e.g., hematopoietic or intestinal stem cells). This would transiently boost NAD+ salvage from nicotinamide, enhancing Sirt1/2 activity and promoting epigenetic maintenance via deacetylation of histones like H3K9ac. Crucially, stem cells are metabolically primed for such shifts—their low basal NAD+ levels make them sensitive to salvage pathway flux. DunedinPACE, as a "speedometer" of aging, might detect this rapid, functional rejuvenation through biomarkers like glycated hemoglobin or inflammatory cytokines. In contrast, Horvath clock, measuring cumulative methylation drift, could lag, reflecting slower, systemic changes.

Testability: Multi-Model Experimental Design

1. Rodent Studies: Administer intermittent rapamycin (e.g., 5 mg/kg weekly) to C57BL/6 mice vs. continuous dosing or controls. Measure:
   • NAD+ levels in sorted hematopoietic stem cells (HSCs) via mass spectrometry.
   • Nampt expression and Sirt1 activity in HSCs.
   • Epigenetic age using Horvath pan-tissue clock, GrimAge, and DunedinPACE from blood samples. Compare with NMN supplementation (e.g., 300 mg/kg/day) alone or combined with rapamycin.
2. Human Pilot: In a short-term trial (e.g., 12 weeks), give weekly rapamycin (5 mg) to healthy adults aged 50-70, with lab monitoring AD trial pharmacokinetics. Track DunedinPACE and Horvath clock from saliva or blood, alongside NAD+ metabolite panels. Include a NMN cohort (500 mg/day) for head-to-head comparison.
3. In Vitro Models: Use human induced pluripotent stem cell-derived organoids to simulate tissue-specific NAD+ metabolism under pulsed mTOR inhibition.

Falsifiability Criteria

• If intermittent rapamycin fails to elevate HSC NAD+ or alter DunedinPACE scores relative to controls, the hypothesis is invalid.
• If Horvath clock shows equal or greater sensitivity than DunedinPACE to rapamycin intervention, the clock-specific prediction fails.
• If NMN co-administration blunts rapamycin-induced changes, it suggests NAD+ saturation overrides mTOR rebound effects.

Implications and Speculative Extensions

This hypothesis challenges the assumption that rapamycin's benefits are solely via sustained mTOR inhibition. Instead, rebound phases might drive beneficial NAD+ cycling, potentially explaining why intermittent dosing outperforms continuous protocols in some rodent lifespan data Off-label rapamycin evidence. It also proposes a hierarchy for biological age clocks: DunedinPACE as a dynamic responder to metabolic interventions, while Horvath clock serves as a chronic exposure marker. If validated, it could lead to personalized rapamycin schedules based on baseline NAD+ levels or epigenetic clock profiles, optimizing healthspan with minimal dosing.